Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
← SearchNorthwestern2023Affirmative
Opening Word document…

Decreased per-unit price outweighs the increase in profits from more insured citizens

Peter Pitts 9, president of the Center for Medicine in the Public Interest and a former FDA associate commissioner, 7/16/9, “Government negotiations in drug prices are dangerous”, http://blogs.reuters.com/great-debate/2009/07/16/drug-price-negotiations-in-the-public-option-dangerous/

An important power of this “public option” has yet to receive much scrutiny, though. The secretary of Health and Human Services will be given the authority to “negotiate” prescription drug prices for the public option. This is a big deal. Government “negotiations” with private vendors almost always mean public officials simply dictating below-market prices. If that holds true in the public option, drug companies that want to participate in the program will be forced to deeply discount their meds. These negotiations might translate into cost-savings for patients up front. But the long term effect would be a stifling of pharmaceutical innovation, leading to fewer new breakthrough medicines and compromised patient care. How so? Developing a new pharmaceutical drug is incredibly expensive. The whole process –including the initial research stages, the countless in-lab experiments required to turn a promising chemical into a usable drug, and the slow, grinding navigation through the FDA’s notoriously difficult safety approval pathway — costs over a billion dollars and takes over a decade for the average drug. Forcing pharmaceutical makers to sell at artificially low prices for a substantial slice of their customer base would drastically reduce their revenues, and leave an increasingly small amount for financing the discovery of new drugs.

Sign in to recut, update, or save this card.